Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day

by Zacks Equity Research

Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day

Zacks Equity Research

Implied Volatility Surging for Moderna (MRNA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Ritujay Ghosh headshot

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

by Ritujay Ghosh

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

Zacks Equity Research

Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.

Zacks Equity Research

Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Sweta Killa headshot

Airline ETF Takes Off: Will The Surge Continue?

by Sweta Killa

Despite the jump, the airline ETF is down about 44% this year.

Neena Mishra headshot

Should You Invest in COVID Themed ETFs?

by Neena Mishra

We highlight three new ETFs that seek to capitalize on coronavirus

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

by Ritujay Ghosh

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

Zacks Equity Research

Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech